Research analysts at Ladenburg Thalmann Financial Services assumed coverage on shares of Alcobra (NASDAQ:ARCT) in a research report issued on Wednesday, Marketbeat reports. The firm set a “buy” rating on the biotechnology company’s stock.
Several other equities analysts have also recently issued reports on the company. Zacks Investment Research cut Alcobra from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. WBB Securities raised Alcobra from a “hold” rating to a “buy” rating and set a $2.00 price objective for the company in a research note on Monday, October 9th. Finally, Roth Capital lowered Alcobra from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $4.00 to $1.00 in a research note on Friday, September 29th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $1.50.
Alcobra (NASDAQ:ARCT) opened at $9.17 on Wednesday. Alcobra has a 1 year low of $5.81 and a 1 year high of $18.06.
ILLEGAL ACTIVITY NOTICE: “Alcobra (ARCT) Earns Buy Rating from Analysts at Ladenburg Thalmann Financial Services” was originally published by Community Financial News and is owned by of Community Financial News. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.com-unik.info/2017/12/01/ladenburg-thalmann-financial-services-initiates-coverage-on-alcobra-arct.html.
Arcturus Therapeutics Ltd, formerly Alcobra Ltd is a Israel-based preclinical-stage biopharmaceutical company primarily focused on the discovery, development and commercialization of ribonucleic acid (RNA) medicines using lipid-mediated delivery system (LUNAR tm) and UNA Oligomer chemistry technologies.The Company is focused on its research and development in therapeutic areas for rare, infectious, fibrotic, and respiratory diseases with unmet medical needs, including rare liver diseases, infectious diseases, cystic fibrosis, nonalcoholic steatohepatitis (NASH) and replicon RNA vaccines.
What are top analysts saying about Alcobra Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Alcobra Ltd. and related companies.